

2014

## Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia

Colleen McEvoy  
*Washington University School of Medicine in St. Louis*

Scott T. Micek  
*Barnes-Jewish Hospital*

Richard M. Reichley  
*Barnes-Jewish Hospital*

Jason Kan  
*Barnes-Jewish Hospital*

Alex Hoban  
*Washington University School of Medicine in St. Louis*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open\\_access\\_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Please let us know how this document benefits you.**

---

### Recommended Citation

McEvoy, Colleen; Micek, Scott T.; Reichley, Richard M.; Kan, Jason; Hoban, Alex; Hoffmann, Justin; Shorr, Andrew F.; and Kollef, Marin H., "Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia." *Surgical Infections*. 15, 3. 283-289. (2014).  
[https://digitalcommons.wustl.edu/open\\_access\\_pubs/3001](https://digitalcommons.wustl.edu/open_access_pubs/3001)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [vanam@wustl.edu](mailto:vanam@wustl.edu).

---

**Authors**

Colleen McEvoy, Scott T. Micek, Richard M. Reichley, Jason Kan, Alex Hoban, Justin Hoffmann, Andrew F. Shorr, and Marin H. Kollef

# Macrolides Are Associated with a Better Survival Rate in Patients Hospitalized with Community-Acquired But Not Healthcare-Associated Pneumonia

Colleen McEvoy,<sup>1</sup> Scott T. Micek,<sup>2</sup> Richard M. Reichley,<sup>3</sup> Jason Kan,<sup>2</sup> Alex Hoban,<sup>1</sup> Justin Hoffmann,<sup>4</sup> Andrew F. Shorr,<sup>5</sup> and Marin H. Kollef<sup>1</sup>

## Abstract

**Background:** Macrolide-based treatment has been associated with survival benefit in patients hospitalized with community-acquired pneumonia (CAP). However, the influence of macrolide therapy in all patients hospitalized with pneumonia, including healthcare-associated pneumonia (HCAP), is unclear.

**Methods:** Analysis of a retrospective single-center cohort.

**Results:** Community-acquired pneumonia was present in 220 (22.5%) of all patients with pneumonia admitted through the emergency department of Barnes-Jewish Hospital, and HCAP was present in 757. Macrolide-based treatment was administered to 411 patients (42.1%). These patients were more likely to have CAP than were patients not receiving macrolide-based therapy (35.3% vs. 13.3%;  $p < 0.001$ ) and had lower scores on the CURB-65 tool, a measure of the severity of illness ( $2.4 \pm 1.5$  vs.  $3.1 \pm 1.3$ ;  $p < 0.001$ ). Patients receiving macrolides also had a lower hospital mortality rate in univariable analysis (12.7% vs. 27.2%;  $p < 0.001$ ). A propensity score analysis showed that macrolide-based treatment was associated with a lower in-hospital mortality rate (adjusted odds ratio [AOR] 0.67; 95% confidence interval [CI] 0.54–0.81;  $p = 0.043$ ). Separate propensity score analyses of patients with CAP (AOR 0.20; 95% CI 0.11–0.34;  $p = 0.003$ ) and HCAP (AOR 0.81; 95% CI 0.65–1.01;  $p = 0.337$ ) produced discordant findings.

**Conclusions:** Macrolide-based treatment was associated with better survival in patients hospitalized with pneumonia. The survival advantage appeared predominantly among patients with CAP.

**P**NEUMONIA IS ONE OF THE LEADING CAUSES of death and the leading cause of hospitalization attributable to an infectious disease [1,2]. For patients hospitalized with pneumonia, 30-d mortality rates are as high as 23%, and annual expenditures in the United States for the treatment of these infections are \$8–\$10 billion [1,3]. Patients hospitalized with pneumonia generally are categorized as having either community-acquired pneumonia (CAP) or healthcare-associated pneumonia (HCAP) on the basis of their exposure to the healthcare system.

Previous studies have suggested that morbidity and mortality rates are reduced with macrolide-based regimens in patients with CAP [4–7]. We are unaware of any analyses examining the impact of macrolide-based treatment in patients hospitalized with pneumonia that included both pa-

tients with CAP and those with HCAP. The increasing population of patients hospitalized with HCAP highlights the importance of determining the clinical significance or lack thereof of macrolide therapy for this important subgroup of patients [8]. Therefore, we conducted a study to determine whether macrolide-based treatment is associated with a survival benefit in a consecutive group of patients hospitalized with pneumonia of either type.

## Patients and Methods

### Study Design

A retrospective cohort analysis was performed of all patients admitted through the emergency department to Barnes-Jewish Hospital (1,250 beds) with a diagnosis of pneumonia

<sup>1</sup>Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri.

<sup>2</sup>Department of Pharmacy and <sup>3</sup>Center for Clinical Excellence, Barnes-Jewish Hospital, St. Louis, Missouri.

<sup>4</sup>St. Louis College of Pharmacy, St. Louis, Missouri.

<sup>5</sup>Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC.

over a 12-mo period (January–December 2010). We excluded patients transferred from other hospitals directly to the wards or to the intensive care unit (ICU). This study was approved by the Washington University School of Medicine Human Studies Committee.

#### Data Source

One of the investigators (RMR) identified potential study patients by the presence of either a primary or secondary International Classification of Diseases-9-CM code indicative of pneumonia. Patients with pneumonia were further identified using the definitions described below. The initial study database was constructed by merging patient-specific data from the automated hospital medical records and microbiology and pharmacy databases of the hospital.

#### Definitions

Diagnosis of pneumonia necessitated both signs and symptoms of infection (i.e., elevated white blood cell count or  $>10\%$  band forms; fever or hypothermia; chest radiograph revealing an infiltrate[s]). One investigator (MHK), blinded to the determination of pneumonia, reviewed the chest images. The diagnosis of a bacterial infection required a positive culture of blood, pleural fluid, sputum, or the lower airways. We also considered a positive urinary antigen test for either *Streptococcus pneumoniae* or *Legionella* spp. as documentation of a bacterial infection.

A HCAP was defined as pneumonia in a patient admitted to the hospital with one of the following risk factors: (1) Residence in a nursing home, rehabilitation hospital, or other long-term nursing facility; (2) hospitalization within the immediately preceding 12 mo; or (3) receiving outpatient hemodialysis, peritoneal dialysis, wound care, or infusion therapy necessitating regular visits to a hospital-based clinic. We also determined the presence of an immunocompromised state, defined as being seropositive for the human immunodeficiency virus (HIV), active malignancy undergoing chemotherapy, or treatment with immunosuppressants (i.e., 10 mg of prednisone or equivalent or a similar agent daily for at least 30 d).

Antimicrobial treatment was classified as being appropriate if the initially prescribed antibiotic regimen was active against the identified pathogen, as judged by *in vitro* susceptibility testing. Patients with pneumonia attributed to *Legionella* spp. were defined as receiving appropriate treatment if their initial antibiotic regimen included a macrolide (e.g., azithromycin) or respiratory quinolone (e.g., moxifloxacin). Appropriate antimicrobial treatment had to be prescribed within 24 h of hospital admission.

#### Statistics

Discrete variables were expressed as counts (percentage) and continuous variables as mean  $\pm$  standard deviation (SD) or medians with the 25th–75th percentile interquartile range (IQR). The  $\chi^2$  test or Fisher exact test was used for categorical variables and the Student *t*-test or the Mann–Whitney U test for continuous variables as appropriate. Multivariable stepwise logistic regression analysis was used to assess the impact of explanatory variables on outcome (in-hospital death). To avoid spurious associations, only variables with a

relation in univariable analysis ( $p \leq 0.1$ ) or a potential plausible relation to the outcome were entered in the logistic regression models.

In addition, the effectiveness of macrolide therapy on the hospital mortality rate was estimated further using propensity scores. These scores were estimated by fitting a logistic regression model. The covariates included in the propensity score model were those measured previous to macrolide treatment having a potential impact on outcome: Age, CURB-65 score, Charlson comorbidity score, gender, chronic obstructive pulmonary disease (COPD), congestive heart failure, chronic renal disease, hematologic or malignant disease, solid tumor, diabetes mellitus, immunosuppression including the presence of human immunodeficiency virus (HIV), dementia, recent hospitalization, admission from a nursing home, and antibiotic treatment within the previous 90 d. Propensity score quintiles were derived, and boxplots of the estimated propensity scores for macrolide-treated and -untreated patients within each quintile of the propensity scores were plotted to assess the validity of the analysis. Finally, we fitted a logistic model for in-hospital death, including as covariates the propensity score and macrolide treatment. Results are presented as adjusted odds ratios (AORs) and 95% confidence intervals (CIs). Additionally, we repeated these analyses for the subgroups of patients with CAP and HCAP. Finally, we performed a logistic regression analysis for the subgroup of patients receiving macrolide therapy to determine the factors associated with survival. For all analyses,  $p$  values  $< 0.05$  were considered significant. We used SPSS for Windows 19.0 (SPSS, Chicago, IL) for all analyses.

#### Results

Nine hundred seventy-seven consecutive patients with pneumonia admitted to Barnes-Jewish Hospital in 2010 were included in the study. The mean age of the patients was  $60.5 \pm 16.9$  y (range 17–102 y) with 544 men (55.7%) and 433 women. Approximately three-quarters of the patients were hospitalized with HCAP (77.5%), and the remainder had CAP. The average CURB-65 score, a measure of illness severity was  $2.8 \pm 1.4$  (median 3.0; 25<sup>th</sup> and 75<sup>th</sup> percentiles 2.0 and 4.0).

Macrolide-based therapy was administered to 411 patients (42.1%). Clarithromycin was given to one patient and azithromycin to 410 patients (99.8%). Patients receiving macrolide-based therapy were statistically younger, were more likely to be African-American, had lower CURB-65 and Charlson comorbidity scores, were less likely to have dementia or be in a bed-bound state, and were less likely to require hemodialysis than patients who did not receive a macrolide-based regimen (Table 1). Patients treated with macrolides were also significantly less likely to be immunosuppressed, have had a recent hospitalization, have been admitted from a nursing home, and have HCAP than patients not treated with a macrolide. The number of HCAP risk factors was statistically lower for patients receiving macrolides ( $1.3 \pm 1.2$  vs.  $2.0 \pm 1.1$ ;  $p < 0.001$ ). Hospital length of stay was significantly shorter for patients receiving macrolide-based therapy ( $10.2 \pm 12.3$  d vs.  $12.7 \pm 15.0$  d;  $p = 0.005$ ).

The pathogens associated most commonly with pneumonia were methicillin-resistant *Staphylococcus aureus*

TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS

	Macrolide Treatment (n=411)	No Macrolide Treatment (n=566)	p value
Age (years ± standard deviation [SD])	58.0 ± 17.0	62.4 ± 16.6	<0.001
Male (%)	225 (54.7)	319 (56.4)	0.616
Race (%)			
White	209 (50.9)	339 (59.9)	0.005
African-American	196 (47.7)	225 (39.8)	
Other	6 ( 1.5)	2 ( 0.4)	
CURB-65 Score ± SD <sup>a</sup>	2.4 ± 1.5	3.1 ± 1.3	<0.001
Charlson Comorbidity Score ± SD	4.7 ± 3.4	6.0 ± 3.4	<0.001
Congestive heart failure (%)	137 (33.3)	195 (34.5)	0.715
Dementia (%)	8 ( 1.9)	36 (16.4)	0.001
COPD (%)	210 (51.1)	302 (53.4)	0.485
End-stage liver disease (%)	7 ( 1.7)	19 ( 3.4)	0.113
Diabetes mellitus (%)	21 ( 5.1)	46 ( 8.1)	0.065
Bed-bound state (%)	12 ( 2.9)	45 ( 8.0)	0.001
Chronic kidney disease (%)	55 (13.4)	102 (18.0)	0.051
Hemodialysis (%)	22 ( 5.4)	50 ( 8.8)	0.040
Solid cell tumor (%)	25 ( 6.1)	53 ( 9.4)	0.062
Lymphoma (%)	26 ( 6.3)	41 ( 7.2)	0.575
Leukemia (%)	17 ( 4.1)	26 ( 4.6)	0.731
HIV infection (%)	15 ( 3.6)	9 ( 1.6)	0.040
Other immunosuppression (%)	107 (26.0)	207 (36.6)	<0.001
HCAP (%)	266 (64.7)	491 (86.7)	<0.001
Recent hospitalization (%)	218 (53.0)	422 (74.6)	<0.001
Admitted from a nursing home (%)	35 ( 8.5)	138 (24.4)	<0.001
Number of HCAP risk factors and immunosuppression (%)			
0	145 (35.3)	75 (13.3)	<0.001
1	90 (21.9)	119 (21.0)	
2	104 (25.3)	165 (29.2)	
3	62 (15.1)	173 (30.6)	
4	10 ( 2.4)	32 ( 5.7)	
5	0	2 ( 0.4)	

<sup>a</sup>CURB-65=Confusion new onset, Urea > 19 mg/dL, Respiratory rate ≥ 30 breaths/min, Blood pressure <90 mm Hg systolic or ≤ 60 mm Hg diastolic, age ≥ 65 years.

Abbreviations: COPD=chronic obstructive pulmonary disease; HCAP=healthcare-acquired pneumonia; HIV=human immunodeficiency virus.

(MRSA)(22.7%), *S. pneumoniae* (19.1%), *Pseudomonas aeruginosa* (19.1%), methicillin-sensitive *S. aureus* (MSSA) (14.1%), and *Haemophilus influenzae* (8.0%) (Table 2). Patients receiving macrolide-based therapy were significantly more likely to be infected with *Legionella* spp., *Haemophilus influenzae*, *S. pneumoniae*, and other *Streptococcus* species than patients not receiving a macrolide. Patients not receiving macrolide-based treatment were more likely to be infected with *Escherichia coli*, *Klebsiella pneumoniae*, MRSA, and *Pseudomonas aeruginosa*. Polymicrobial infection occurred in 139 patients (14.2%) and was less common in patients treated with macrolides. Secondary bacteremia developed in

TABLE 2. PATHOGENS ASSOCIATED WITH PNEUMONIA (No. [%])

	Macrolide Treatment (n=411)	No Macrolide Treatment (n=566)	P value
<i>Achromobacter</i> spp.	2 ( 0.5)	9 ( 1.6)	0.132
<i>Acinetobacter</i> spp.	9 ( 2.2)	38 ( 6.7)	0.001
<i>Burkholderia</i> spp.	0	1 ( 0.2)	1.000
<i>Citrobacter</i> spp.	0	4 ( 0.7)	0.143
EBSL-producing Enterobacteriaceae	2 ( 0.5)	5 ( 0.9)	0.705
<i>Enterobacter</i> spp.	6 ( 1.5)	13 ( 2.3)	0.350
<i>Escherichia coli</i>	10 ( 2.4)	43 ( 7.6)	<0.001
<i>Haemophilus influenzae</i>	46 (11.2)	32 ( 5.7)	0.002
<i>Klebsiella pneumoniae</i>	12 ( 2.9)	43 ( 7.6)	0.002
<i>Legionella</i> spp.	11 ( 2.7)	1 ( 0.2)	0.001
<i>Moraxella</i> spp.	9 ( 2.2)	11 ( 1.9)	0.788
<i>Morganella</i> spp.	0	4 ( 0.7)	0.143
MRSA	74 (18.0)	148 (26.1)	0.003
MSSA	63 (15.3)	75 (13.3)	0.357
<i>Mycoplasma pneumoniae</i>	3 ( 0.7)	0	0.074
<i>Proteus</i> spp.	5 ( 1.2)	17 ( 3.0)	0.063
<i>Providencia</i> spp.	0	2 ( 0.4)	0.512
<i>Pseudomonas aeruginosa</i>	46 (11.2)	141 (24.9)	<0.001
<i>Serratia marcescens</i>	2 ( 0.5)	11 ( 1.9)	0.086
<i>Stenotrophomonas maltophilia</i>	4 ( 1.0)	10 ( 1.8)	0.416
<i>Streptococcus pneumoniae</i>	126 (30.7)	61 (10.8)	<0.001
Other <i>Streptococcus</i> spp.	25 ( 6.1)	15 ( 2.7)	0.008
Polymicrobial infection	40 ( 9.7)	99 (17.5)	0.001
Positive blood culture	136 (33.1)	200 (35.3)	0.466

Abbreviations: ESBL=extended-spectrum β-lactamase; MRSA= methicillin-resistant *Staphylococcus aureus*; MSSA= methicillin-sensitive *S. aureus*.

336 patients (34.4%) with similar occurrences in patients treated with and those not receiving a macrolide drug.

The overall hospital mortality rate was 21.1% (n=206). The rate was lower among macrolide-treated patients (12.7% vs. 27.2%; p<0.001). In-hospital death was associated with older age, greater CURB-65 and Charlson comorbidity scores, whereas race, end-stage liver disease, hemodialysis, immunosuppression, recent hospitalization, admission from a nursing home, and HCAP (Table 3). The number of HCAP risk factors was statistically greater among nonsurvivors (2.0 ± 1.2 vs. 1.6 ± 1.2; p<0.001). The hospital length of stay was similar for nonsurvivors and survivors (12.2 ± 19.6 d vs. 11.5 ± 12.1 days; p=0.495). Kaplan-Meier curve analysis demonstrated that hospital survival was significantly greater for macrolide-treated patients (both CAP and HCAP), and the survival difference was more pronounced for the CAP subgroup (Fig. 1). There was no difference in survival of the HCAP patients receiving and not receiving macrolide-based therapy.

TABLE 3. PREDICTORS OF IN-HOSPITAL DEATH

	Nonsurvivors (n=206)	Survivors (n=771)	p value
Age (years $\pm$ standard deviation [SD])	64.5 $\pm$ 15.6	59.5 $\pm$ 17.1	<0.001
Male (%)	117 (56.8)	427 (55.4)	0.717
Race (%)			
White	132 (64.1)	416 (54.0)	0.013
African-American	71 (34.5)	350 (45.4)	
Other	3 ( 1.5)	5 ( 0.6)	
CURB-65 Score $\pm$ SD	3.8 $\pm$ 0.9	2.6 $\pm$ 1.5	<0.001
Charlson comorbidity score $\pm$ SD	6.9 $\pm$ 3.5	5.1 $\pm$ 3.4	<0.001
Congestive heart failure (%)	76 (36.9)	256 (33.2)	0.321
Dementia (%)	13 ( 6.3)	31 ( 4.0)	0.159
COPD (%)	100 (48.5)	412 (53.4)	0.212
End-stage liver disease (%)	15 ( 7.3)	11 ( 1.4)	<0.001
Diabetes (%)	18 ( 8.7)	49 ( 6.4)	0.229
Bed-bound state (%)	7 ( 3.4)	50 ( 6.5)	0.093
Chronic kidney disease (%)	43 (20.9)	114 (14.8)	0.035
Hemodialysis (%)	25 (12.1)	47 ( 6.1)	0.003
Solid tumor (%)	19 ( 9.2)	59 ( 7.7)	0.460
Lymphoma (%)	17 ( 8.3)	50 ( 6.5)	0.373
Leukemia (%)	13 ( 6.3)	30 ( 3.9)	0.133
HIV (%)	6 ( 2.9)	18 ( 2.3)	0.634
Other immunosuppression (%)	82 (39.8)	232 (30.1)	0.008
HCAP	180 (87.4)	577 (74.8)	<0.001
Recent hospitalization	155 (75.2)	485 (62.9)	0.001
Admitted from nursing home	47 (22.8)	126 (16.3)	0.031
Number of HCAP risk factors and immunosuppression			
0	26 (12.6)	194 (25.2)	<0.001
1	47 (22.8)	162 (21.0)	
2	52 (25.2)	217 (28.1)	
3	70 (34.0)	165 (21.4)	
4	9 ( 4.4)	33 ( 4.2)	
5	2 ( 1.0)	0	

<sup>a</sup>CURB-65 = Confusion new onset, Urea >19 mg/dL, Respiratory rate  $\geq$ 30 breaths/min, Blood pressure <90 mm Hg systolic or  $\leq$ 60 mm Hg diastolic, age  $\geq$ 65 y.

Abbreviations: COPD=chronic obstructive pulmonary disease; HCAP=healthcare-acquired pneumonia; HIV=human immunodeficiency virus.

A logistic regression analysis adjusted for severity of illness (CURB-65, Charlson comorbidity score) and potential confounding factors (congestive heart failure, COPD, dementia, end-stage liver disease, diabetes, solid tumor, lymphoma, leukemia, HIV infection, age, gender, recent hospitalization, admission from a nursing home, immunosuppression, and previous antibiotic administration) found that macrolide use was significantly associated with survival (AOR 0.63; 95% CI 0.52–0.77;  $p=0.021$ ). Similarly, the propensity score analysis found macrolide use to be significantly associated with a lower mortality rate (AOR 0.67; 95% CI 0.54–0.81;  $p=0.043$ ). The overlapping of the propensity scores for macrolide-treated and non-macrolide-treated patients within each propensity score quintile reinforced the





FIG. 1. Kaplan-Meier curves for patients with community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP) receiving macrolide-based (broken line) and non-macrolide-based (solid line) regimens.

validity of the propensity score analysis (Fig. 2). Propensity score analysis for the subgroup of patients with CAP demonstrated macrolide use to be associated with a lower mortality rate (AOR 0.20; 95% CI 0.11–0.34;  $p=0.003$ ); however, for the subgroup with HCAP, there was no demonstrable effect of macrolide treatment on the mortality rate (AOR 0.81; 95% CI 0.65–1.01;  $p=0.337$ ).

A logistic regression analysis of the subgroup of patients receiving macrolide therapy identified only two independent predictors of a lower mortality rate despite including all identified co-morbidities and the individual HCAP risks. Absence of mechanical ventilation (AOR 0.33; 95% CI 0.25–0.44;  $p<0.001$ ) and lower CURB-65 scores (one-point decrements)(AOR 0.52; 95% CI 0.44–0.61;  $p<0.001$ ) were independently associated with a lower mortality rate among macrolide-treated patients (Hosmer-Lemeshow goodness-of-fit  $p=0.783$ ).

## Discussion

We demonstrated that the use of macrolide-based therapy was associated with a lower risk of in-hospital death among



**FIG. 2.** Box plots of propensity score quintiles (Q) for patients with and without macrolide-based therapy.

consecutive patients admitted to the hospital with pneumonia. However, our sensitivity analysis suggests that this benefit is seen primarily in patients with CAP, not those with HCAP. Not surprisingly, the distribution of pathogens in patients with CAP and HCAP differed, with *S. pneumoniae* being the predominant bacterium isolated in patients with CAP and *S. aureus* and *P. aeruginosa* being the most common bacterial pathogens associated with HCAP. We also found that among patients treated with macrolides, only mechanical ventilation and CURB-65 scores predicted the risk of death.

Previous studies have demonstrated the potential benefit of macrolide-based therapy in patients with CAP. Asadi et al. conducted a meta-analysis that included 23 studies and 137,574 patients with CAP [7]. Overall, macrolide use was associated with a statistically significant mortality reduction compared with nonmacrolide use. However, there was no survival advantage, and study heterogeneity was reduced when analyses were restricted to randomized trials or to patients treated with guideline-concordant antibiotics (macrolide/beta-lactam or respiratory fluoroquinolones). Another recent meta-analysis reviewed 28 studies of CAP, with the main objective being to estimate the mortality rate and the proportion with treatment failure using regimens containing atypical antibiotic coverage compared with those that had typical coverage only [9]. There was no difference in the mortality rates between the atypical-drug arm and the non-atypical arm. The atypical arm showed an insignificant trend toward greater clinical success and a significant advantage in bacterial eradication, which disappeared when evaluating methodologically high-quality studies alone. Taken together, these meta-analyses, as well as other clinical studies, suggest that guideline-based coverage of atypical pathogens in CAP may be most important in determining clinical outcomes, including the mortality rate and bacterial eradication [7,9,10].

Other investigators have found mixed results with the use of macrolides in the treatment of community-based respiratory infections. Martín-Loeches et al. used a propensity score analysis and found that macrolide-based treatment was not associated with a better survival rate in critically ill patients with viral pneumonia attributed to influenza virus H1N1 [11]. However, recent studies in COPD [12], cystic fibrosis

[13,14], bronchiolitis obliterans syndrome [15], and asthma [16] suggest that macrolides may confer benefit to patients with community-based respiratory illnesses that are at least partially attributed to respiratory infections for their pathogenesis. In addition to their antimicrobial properties, macrolides have been believed to benefit patients with inflammatory lung diseases, including CAP, through anti-inflammatory mechanisms. Azithromycin significantly reduces airway neutrophilia and interleukin-8 mRNA expression [17]. The anti-inflammatory and immunomodulatory activity of macrolides purportedly contribute to their successful use as therapeutic agents for chronic lung diseases, including cystic fibrosis and diffuse panbronchiolitis [18].

Recent increasing rates of macrolide resistance in *S. pneumoniae* have brought into question the overall utility of this class of antibiotics for use in CAP [19]. However, macrolides have antimicrobial activity against *P. aeruginosa* in eukaryotic media through increased uptake and reduced efflux of the drug despite high minimum inhibitory concentrations (MICs) on conventional media (cation-adjusted Mueller–Hinton broth) [20]. Despite these observations, the reported beneficial influence of macrolide therapy on outcomes in acute pneumonia is still observed primarily in CAP [7]. The potential antimicrobial influence of macrolides on *P. aeruginosa* may explain, in part, their efficacy in patients with cystic fibrosis and other chronic lung diseases [13,14].

Our current study has several major limitations. First, we restricted our analysis to patients with microbiologically confirmed bacterial infection. This likely contributed to the smaller number of patients with CAP compared with HCAP [21]. We have shown previously that patients with culture-negative HCAP do as well with traditional CAP treatment as with treatment targeting HCAP [22]. It is possible that had we included culture-negative patients in our study, we might have seen a mortality benefit with macrolide therapy in patients with HCAP. Moreover, it is possible that some of our positive cultures from the respiratory tract reflected colonization rather than true infection. This seems to be a lesser concern, however, given the adjudication of the radiographic criteria and the relatively large percentage of patients with concomitant positive blood cultures. Second, the criteria for HCAP are somewhat arbitrary and have been disputed as markers of antibiotic resistance in patients presenting with pneumonia [23]. Third, we modified our criteria for HCAP from the 2005 American Thoracic Society/Infectious Disease Society of America guidelines by including patients with hospitalization up to one year earlier [24]. This was done because of the limited number of good-quality studies reporting on the relation of timing of prior hospitalization and antibiotic exposure to subsequent development of antibiotic-resistant infections and the results of a recent meta-analysis suggesting that the effects of previous antibiotic prescription on resistance emergence were conspicuous for as long as 12 mo after exposure [25].

It is important to note that we did not evaluate systematically for concomitant viral infection. Given the possibility that some patients with acute viral infections will present with pneumonia, we may have diluted the influence of macrolide therapy, especially among patients with HCAP, given the recent Spanish experience [11]. It also is possible

that the difference in outcomes associated with macrolide therapy between patients with CAP and those with HCAP was attributable to some underdetermined confounding factor. For example, there were more patients with immunosuppression in the HCAP group, which may have influenced the patients' response to macrolide therapy. Finally, all nursing home patients do not appear to be the same. Previous investigators have shown that among nursing home patients, prior antibiotic administration and daily living activity are the best predictors of infection with HCAP pathogens [26]. However, we captured the presence of a bed-bound state and prior antibiotic exposure in our analysis, so our assessment of the nursing home patients should have been complete in this regard.

In conclusion, our data suggest that macrolide therapy is most effective in patients with CAP, and we could not demonstrate any influence of these drugs on the survival of patients with HCAP. This suggests that the use of macrolides in pneumonia should be based on the published guidelines that recommend their use when a clinical or epidemiologic suspicion of infection with atypical pathogens exists, primarily in patients with CAP [3]. The clinical use of risk factors to identify patients at risk for HCAP may assist clinicians in detecting patients who are unlikely to benefit from macrolide therapy.

#### Author Disclosure Statement

The authors have no conflicts of interest in relation to this work. Dr. Kollef's efforts were supported by the Barnes-Jewish Hospital Foundation.

#### References

- File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. *Postgrad Med* 2010; 122:130–141.
- Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. *JAMA* 2013;309:355–363.
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007; 44(Suppl 2):S27–S72.
- Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis* 2003;36:389–395.
- Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. *Chest* 2007;131:466–473.
- Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. *Eur Respir J* 2009;33:153–159.
- Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: A systematic review and meta-analysis. *Clin Infect Dis* 2012;55:371–380.
- Kollef MH, Morrow LE, Baughman RP, et al. Health care-associated pneumonia (HCAP): A critical appraisal to improve identification, management, and outcomes. Proceedings of the HCAP Summit. *Clin Infect Dis* 2008; 46(Suppl 4):S296–S334.
- Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. *Cochrane Database Syst Rev* 2012;9:CD004418.
- Asadi L, Eurich DT, Gamble JM, et al. Impact of guideline-concordant antibiotics and macrolide/ $\beta$ -lactam combinations in 3203 patients hospitalized with pneumonia: Prospective cohort study. *Clin Microbiol Infect* 2013;19: 257–264.
- Martín-Loeches I, Bermejo-Martin JF, Vallés J, et al. Macrolide-based regimens in absence of bacterial coinfection in critically ill H1N1 patients with primary viral pneumonia. *Intensive Care Med* 2013;39:693–702.
- Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. *N Engl J Med* 2011;365:689–698.
- Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with *Pseudomonas aeruginosa*: A randomized controlled trial. *JAMA* 2010;303:1707–1715.
- Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: A randomized controlled trial. *JAMA* 2003;290:1749–1756.
- Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. *J Heart Lung Transplant* 2010;29:531–537.
- Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. *Thorax* 2013;68:322–329.
- Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. *Am J Respir Crit Care Med* 2006;174:566–570.
- Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. *Eur Respir J* 2012 (Epub ahead of print).
- Low DE. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by *Streptococcus pneumoniae*? (Should macrolide monotherapy be used for mild pneumonia?). *Infect Dis Clin North Am* 2013;27:87–97.
- Buyck JM, Plésiat P, Traore H, et al. Increased susceptibility of *Pseudomonas aeruginosa* to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. *Clin Infect Dis* 2012;55: 534–542.
- Blaschke AJ. Interpreting assays for the detection of *Streptococcus pneumoniae*. *Clin Infect Dis* 2011;52(Suppl 4):S331–S337.
- Labelle AJ, Arnold H, Reichley RM, et al. A comparison of culture-positive and culture-negative health-care-associated pneumonia. *Chest* 2010;137:1130–1137.
- Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia a distinct entity needing specific therapy? *Curr Opin Infect Dis* 2012;25:166–175.
- American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-



- associated pneumonia. *Am J Respir Crit Care Med* 2005; 171:388–416.
25. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis. *BMJ* 2010;340:c2096.
  26. El Solh AA, Pietrantonio C, Bhat A, et al. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. *Clin Infect Dis* 2004;39:474–480.

Address correspondence to:

*Dr. Marin H. Kollef*  
*Division of Pulmonary and Critical Care Medicine*  
*Washington University School of Medicine*  
*660 South Euclid Ave. Campus Box 8052*  
*St. Louis, MO 63110*

*E-mail: mkollef@dom.wustl.edu*